Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus BRONKOMETER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus BRONKOMETER.
AEROLATE III vs BRONKOMETER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator